newsThe trial will assess the safety, tolerability and immunogenicity of…
27 August 2020 | By Hannah Balfour (European Pharmaceutical Review)
The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.